ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Trio of Texas biotech firms win total of $50 million in grants for cancer

by Ryan Cross
August 31, 2018 | APPEARED IN VOLUME 96, ISSUE 35

The Cancer Prevention & Research Institute of Texas is supporting 16 Texas institutions with more than $177 million. Three grants, totaling more than $50 million, are heading to a trio of biotech firms. Forbius will receive nearly $19 million to evaluate an anti-EGFR antibody-drug conjugate in Phase IIa clinical trials. Korysso Therapeutics will receive nearly $20 million to develop compounds that treat neurological damage caused by cancer chemotherapy. And CerRx will receive nearly $12 million to test combination drug therapies in lymphoma.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment